Article
In vitro evaluation of factor IX as novel treatment for factor XI deficiency
2019-04-19
Abstract excerpt
<h4>ABSTRACT</h4> Factor XI deficiency is associated with mild to moderate bleeding upon injury. Treatment of bleeding in patients can be a challenge due to the limited availability of factor XI concentrates that may also have thrombotic side effects, and the volume overload as a result of plasma transfusion. In our in vitro study, we established that recombinant factor IX concentrate Benefix® (Pfizer) was able t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 47b4574e-ec3a-5662-89b0-6c4559d0d902
- DOI
- 10.1101/614180
